Please note: The information displayed on this page might be outdated.
Horama: HORAMA develops new gene therapies for rare inherited ocular diseases to improve or restore patient autonomy and reduce healthcare costs for society. HORAMA’s approach is based on vector technology using non-pathogenic, recombinant adeno-associated viruses (rAAV). The rAAV carrying the therapeutic gene of interest penetrates the target retinal cells, inducing the expression of the functional protein. The company's lead candidate is HORA-PDE6B, which is in Phase I/II clinical trials with an indication in PDE6B retinitis pigmentosa. The second product will enter in the clinic in H1 2019

The company raised EUR 22.5 million of Series B venture funding from Kurma Partners, Pontifax Venture Capital, Fund+ on November 8, 2017. V-Bio, Turenne Capital, IdInvest Partners, GO Capital, Sham Innovation Santé and Omnes Capital also participated in the round.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Ophthalmology, Rare Disease
Industry
Biotechnology
Listing
Private
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy, Gene Therapy
Website:
Profiles:
Address:
27 rue du Faubourg Saint-Jacques
Paris, 75014
France

Company Participants at European Biotech Investor Day 2020

  • Christine Placet, CEO
  • Rodolphe Clerval, Chief Business Officer